REFERENCES
1. Duan J, Liu D, Zhao Z, et al. Short-term duration of diabetic retinopathy as a predictor for development of diabetic kidney disease. J Transl Int Med. 2023;11:449-58.
2. Liu D, Chen X, He W, et al. Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy. Integr Med Nephrol Androl. 2024;11:e23-00029.
3. Zhao H, Zhao T, Li P. Gut microbiota-derived metabolites: a new perspective of traditional chinese medicine against diabetic kidney disease. Integr Med Nephrol Androl. 2024;11:e23-00024.
4. Zhao H, Li Z, Yan M, et al. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle. J Transl Int Med. 2024;12:157-69.
5. Chung JY, Lan H, Tang PM. New insights into traditional chinese medicine in treatment of diabetic nephropathy. Integr Med Nephrol Androl. 2023;10:e00026.
6. Wu C, Wang J, Zhang R, et al. Research progress on Cornus officinalis and its active compounds in the treatment of diabetic nephropathy. Front Pharmacol. 2023;14:1207777.
7. Zhang R, Wang J, Wu C, Wang L, Liu P, Li P. Lipidomics-based natural products for chronic kidney disease treatment. Heliyon. 2025;11:e41620.
8. Deng Y, Zhu H, Xing J, et al. The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease. Front Physiol. 2025;16:1624077.
9. Ma L, Yan M, Kong X, et al. Association of EPHX2 R287Q polymorphism with diabetic nephropathy in Chinese type 2 diabetic patients. J Diabetes Res. 2018;2018:2786470.
10. Trombetta M, Bonetti S, Boselli ML, et al. PPARG2 Pro12Ala and ADAMTS9 rs4607103 as “insulin resistance loci” and “insulin secretion loci” in Italian individuals. The GENFIEV study and the verona newly diagnosed type 2 diabetes study (VNDS) 4. Acta Diabetol. 2013;50:401-8.
11. Yang R, Jin F, Wang L, et al. Prediction and identification of power performance using polygenic models of three single-nucleotide polymorphisms in Chinese elite athletes. Front Genet. 2021;12:726552.
12. Du F, Yang KJ, Piao LS. Correlation between PPARGC1A gene Rs8192678 G>A polymorphism and susceptibility to type-2 diabetes. Open Life Sci. 2019;14:43-52.
13. Xia W, Chen N, Peng W, et al. Systematic meta-analysis revealed an association of PGC-1α rs8192678 polymorphism in type 2 diabetes mellitus. Dis Markers. 2019;2019:2970401.
14. Seman N, Othman SH. Recent progress in genetics and epigenetics research on diabetic nephropathy in Malaysia. J Diabetes Res. 2023;2023:9053580.
15. Alberti KGMM, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation. Diabet Med. 1998;15:539-53.
16. Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1-S127.
17. Committee on the Chinese Guidelines for Lipid Management. Chinese guideline for lipid management (primary care version 2024). Chin J Cardiol. 2024;52:330-7.
18. Carvalho MO, Duque AP, Huguenin GVB, Felix Mediano MF, Rodrigues Júnior LF. Increased cardiometabolic risk in dynapenic obesity: results from the study of workers’ health (ESAT). Life. 2024;14:1174.
19. Liu P, Ma L, Zhao H, et al. Association between LXR-α and ABCA1 Gene Polymorphisms and the Risk of Diabetic Kidney Disease in Patients with Type 2 Diabetes Mellitus in a Chinese Han Population. J Diabetes Res. 2020;2020:8721536.
20. Freedman BI, Langefeld CD, Lu L, et al. Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet. 2011;7:e1002150.
21. Wang H, Su J, Yu M, Xia Y, Wei Y. PGC-1α in osteoarthritic chondrocytes: From mechanism to target of action. Front Pharmacol. 2023;14:1169019.
22. Savla SR, Prabhavalkar KS, Bhatt LK. Liver X receptor: a potential target in the treatment of atherosclerosis. Expert Opin Ther Targets. 2022;26:645-58.
23. Rasheed A, Cummins CL. Beyond the foam cell: the role of LXRs in preventing atherogenesis. Int J Mol Sci. 2018;19:2307.
24. Ahsan F, Oliveri F, Goud HK, et al. Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cureus. 2020;12:e10446.
25. Luo L, Chua YB, Liu T, et al. Muscle injuries induce a prostacyclin-PPARγ/PGC1a-FAO spike that boosts regeneration. Adv Sci. 2023;10:e2301519.
26. Ahrens M, Ammerpohl O, von Schönfels W, et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab. 2013;18:296-302.
27. Chambers JM, Wingert RA. PGC-1α in disease: recent renal insights into a versatile metabolic regulator. Cells. 2020;9:2234.
28. Besse-Patin A, Léveillé M, Oropeza D, Nguyen BN, Prat A, Estall JL. Estrogen signals through peroxisome proliferator-activated receptor-γ coactivator 1α to reduce oxidative damage associated with diet-induced fatty liver disease. Gastroenterology. 2017;152:243-56.
29. Ghosh S, Lertwattanarak R, Lefort N, et al. Reduction in reactive oxygen species production by mitochondria from elderly subjects with normal and impaired glucose tolerance. Diabetes. 2011;60:2051-60.
30. Hammarstedt A, Jansson PA, Wesslau C, Yang X, Smith U. Reduced expression of PGC-1 and insulin-signaling molecules in adipose tissue is associated with insulin resistance. Biochem Biophys Res Commun. 2003;301:578-82.
31. Zhang RN, Shen F, Pan Q, Cao HX, Chen GY, Fan JG. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27:3863-76.
32. Lin YC, Chang PF, Chang MH, Ni YH. A common variant in the peroxisome proliferator-activated receptor-γ coactivator-1α gene is associated with nonalcoholic fatty liver disease in obese children. Am J Clin Nutr. 2013;97:326-31.
33. Goyenechea E, Crujeiras AB, Abete I, Parra D, Martínez JA. Enhanced short-term improvement of insulin response to a low-caloric diet in obese carriers the Gly482Ser variant of the PGC-1alpha gene. Diabetes Res Clin Pract. 2008;82:190-6.
